The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration

This publication has 42 references indexed in Scilit:

• Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention
  Circulation, 2001
• Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris
  The American Journal of Cardiology, 1999
• Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial
  The American Journal of Cardiology, 1998
• Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease
  Circulation, 1997
• Low-molecular-weight heparin during instability in coronary artery disease
  The Lancet, 1996
• Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
  New England Journal of Medicine, 1995
• Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
  Circulation, 1993
• Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)
  British Journal of Haematology, 1992
• Low molecular weight heparin
  Blood, 1992
• Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty.
  Heart, 1990